![]() | |
Clinical data | |
---|---|
Trade names | HMS, Medrocort, others |
Other names | NSC-63278; Hydroxymethylprogesterone; Methylhydroxyprogesterone; Hydroxymesterone; 6α-Methyl-11β-hydroxyprogesterone; 6α-Methyl-11β-hydroxypregn-4-ene-3,20-dione |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a606003 |
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.018.371 |
Chemical and physical data | |
Formula | C22H32O3 |
Molar mass | 344.495 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Medrysone ( INN, USAN) (brand names HMS, Medrocort, others; former developmental code name NSC-63278), also known as hydroxymethylprogesterone, methylhydroxyprogesterone, or hydroxymesterone, as well as 6α-methyl-11β-hydroxyprogesterone or 6α-methyl-11β-hydroxypregn-4-ene-3,20-dione, is a synthetic glucocorticoid that is or has been used in the treatment of inflammatory eye diseases. [1] [2] [3] It has been discontinued in the United States. [4] Although it is very similar in structure to progesterone, [5] neither progestogenic nor androgenic activity has been demonstrated for or attributed to medrysone. [6] [7] [8]
In 2021, medrysone was one of the 12 compounds identified in sludge samples taken from 12 wastewater treatment plants in California that were associated with estrogenic activity in in vitro. [9]
![]() | |
Clinical data | |
---|---|
Trade names | HMS, Medrocort, others |
Other names | NSC-63278; Hydroxymethylprogesterone; Methylhydroxyprogesterone; Hydroxymesterone; 6α-Methyl-11β-hydroxyprogesterone; 6α-Methyl-11β-hydroxypregn-4-ene-3,20-dione |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a606003 |
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.018.371 |
Chemical and physical data | |
Formula | C22H32O3 |
Molar mass | 344.495 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Medrysone ( INN, USAN) (brand names HMS, Medrocort, others; former developmental code name NSC-63278), also known as hydroxymethylprogesterone, methylhydroxyprogesterone, or hydroxymesterone, as well as 6α-methyl-11β-hydroxyprogesterone or 6α-methyl-11β-hydroxypregn-4-ene-3,20-dione, is a synthetic glucocorticoid that is or has been used in the treatment of inflammatory eye diseases. [1] [2] [3] It has been discontinued in the United States. [4] Although it is very similar in structure to progesterone, [5] neither progestogenic nor androgenic activity has been demonstrated for or attributed to medrysone. [6] [7] [8]
In 2021, medrysone was one of the 12 compounds identified in sludge samples taken from 12 wastewater treatment plants in California that were associated with estrogenic activity in in vitro. [9]